New hope for Tough-to-Treat breast cancer: major trial tests promising drug
NCT ID NCT07461454
Summary
This study is for people with a specific type of advanced breast cancer (HR+/HER2-) that has spread or returned and is no longer responding to standard chemotherapy. It will compare a new investigational drug called YL202 against several currently available treatment options chosen by doctors. The main goal is to see if YL202 can better control the cancer and help patients live longer without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201321, China
Contact
Conditions
Explore the condition pages connected to this study.